Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

We provide more details on some of the top companies in the Nasdaq 100 index that are dragging the QQQ ETF this year.

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...

Shares of Vertex Pharmaceuticals Incorporated VRTX rose 2.4% on its cystic fibrosis drug Alyftrek getting approval in the United Kingdom. Shares of Tesla, Inc. TSLA plummeted 15.4% on the broad-based ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

Dow Jones futures rose modestly overnight, along with S&P 500 futures and Nasdaq futures. CPI inflation report early Wednesday.The stock market reversed sharply lower Tuesday morning as President ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

While the stock rose 7% in 2024, that gain was split between a 318% rocket ride higher from where it ended 2023 (at $28.43) to its March 13 record close of $118.81, and the 74% plunge from there to ...